Ixekizumab in nail psoriasis
Corresponding Author
Annunziata Dattola
Department of Dermatology, University of Rome “Tor Vergata”, Rome, Italy
Correspondence
Annunziata Dattola, Department of Dermatology, University of Rome Tor Vergata, V.le Oxford 81, 00133 Rome, Italy.
Email: [email protected]
Search for more papers by this authorValeria Manfreda
Department of Dermatology, University of Rome “Tor Vergata”, Rome, Italy
Search for more papers by this authorSara Mazzilli
Department of Dermatology, University of Rome “Tor Vergata”, Rome, Italy
Search for more papers by this authorLuca Bianchi
Department of Dermatology, University of Rome “Tor Vergata”, Rome, Italy
Search for more papers by this authorAlessandro Giunta
Department of Dermatology, University of Rome “Tor Vergata”, Rome, Italy
Search for more papers by this authorCorresponding Author
Annunziata Dattola
Department of Dermatology, University of Rome “Tor Vergata”, Rome, Italy
Correspondence
Annunziata Dattola, Department of Dermatology, University of Rome Tor Vergata, V.le Oxford 81, 00133 Rome, Italy.
Email: [email protected]
Search for more papers by this authorValeria Manfreda
Department of Dermatology, University of Rome “Tor Vergata”, Rome, Italy
Search for more papers by this authorSara Mazzilli
Department of Dermatology, University of Rome “Tor Vergata”, Rome, Italy
Search for more papers by this authorLuca Bianchi
Department of Dermatology, University of Rome “Tor Vergata”, Rome, Italy
Search for more papers by this authorAlessandro Giunta
Department of Dermatology, University of Rome “Tor Vergata”, Rome, Italy
Search for more papers by this author
REFERENCES
- 1Piraccini BM, Starace M. Optimal management of nail disease in patients with psoriasis. Psoriasis (Auckl). 2015; 5: 25-33.
- 2Klaassen KM, van de Kerkhof PC, Pasch MC. Nail psoriasis, the unknown burden of disease. J Eur Acad Dermatol Venereol. 2014; 28(12): 1690-1695.
- 3Bardazzi F, Starace M, Bruni F, Magnano M, Piraccini BM, Alessandrini A. Nail psoriasis: an updated review and expert opinion on available treatments, including biologics. Acta Derm Venereol. 2018; 99(6): 516-523.
- 4Starostzik C. Psoriasis nails need motivation and patience. MMW Fortschr Med. 2016; 158(11): 8.
- 5Blauvelt A, Gooderham M, Iversen L, et al. Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3). J Am Acad Dermatol. 2017; 77(5): 855-862.
- 6van de Kerkhof P, Guenther L, Gottlieb AB, et al. Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3. J Eur Acad Dermatol Venereol. 2017; 31(3): 477-482. https://doi.org/10.1111/jdv.14033.
